74° Mostly Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

148.62 +7.69 (+5.45%)

Delayed Quote Updated: 1:03 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Merck & Co. (NYSE:MRK) Posts Q3 Earnings Beat as EPS Surprise Offsets In-Line Sales Guidance ↗

Today 9:18 EDT

Via Chartmill

Topics Earnings

Merck (NYSE:MRK) delivers impressive Q3 2026

Today 7:30 EDT

Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q3 2026, with revenue rising 4.7% year on year to $18.09 billion. Th...

Via StockStory

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

Today 6:30 EDT

From Merck & Co., Inc.

Via Business Wire

Could Revolution Medicines Be a Millionaire-Maker Stock? ↗

Today 5:04 EDT

The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.

Via The Motley Fool

Merck (MRK) reports Q3: everything you need to know ahead of earnings

October 27, 2026

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday before market open. Here’s what investors should know. Merck beat ana...

Via StockStory

Topics Artificial Intelligence

Dow Jones Top Gainers in Today's Session: 3M Leads ↗

October 20, 2026

Via Chartmill

Topics Stocks

Dow Jones Top Gainers on Oct. 20, 2026: MMM, UNH, MRK Lead Session ↗

October 20, 2026

Via Chartmill

Topics Stocks

Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid? ↗

October 27, 2026

Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.

Via MarketBeat

Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts ↗

October 26, 2026

Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab...

Via MarketBeat

S&P 500 Top Movers: Gainers and Losers in Today's US Session ↗

October 26, 2026

Via Chartmill

Topics Stocks

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗

October 26, 2026

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

Via MarketBeat

Topics Artificial Intelligence

Merck (NYSE:MRK) Nears Breakout Setup With Strong Technical Ratings ↗

October 20, 2026

Via Chartmill

Merck & Co. (NYSE:MRK): A Quality Investing Case With Strong ROIC but Revenue Growth Concerns ↗

October 15, 2026

Via Chartmill

KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

October 26, 2026

From Merck & Co., Inc.

Via Business Wire

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer

October 26, 2026

From Merck & Co., Inc.

Via Business Wire

A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets

October 26, 2026

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

From Biotech Insider

Via GlobeNewswire

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗

October 23, 2026

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

Via MarketBeat

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium

October 22, 2026

From Merck & Co., Inc.

Via Business Wire

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

October 21, 2026

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

From FN Media

Via GlobeNewswire

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

October 21, 2026

EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END

Via FinancialNewsMedia

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 ↗

October 21, 2026

The market has rewarded this biotech for its breakthroughs.

Via The Motley Fool

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

October 21, 2026

From Merck & Co., Inc.

Via Business Wire

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice ↗

October 21, 2026

This company made headlines with its coronavirus vaccine.

Via The Motley Fool

2 High-Flying Dividend Stocks to Buy and Hold for a Decade ↗

October 19, 2026

They may just be getting started.

Via The Motley Fool

Topics Intellectual Property

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗

October 19, 2026

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

Via MarketBeat

Topics Artificial Intelligence

If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys ↗

October 17, 2026

These funds can help you weather any storm that might be on the way.

Via The Motley Fool

Topics ETFs Stocks

Novo Nordisk and Eli Lilly Just Got Some Fantastic News ↗

October 16, 2026

A new government-funded study found that GLP-1 drugs slow the aging process in mice.

Via The Motley Fool

Discover which dow jones stocks are making waves on Thursday. ↗

October 15, 2026

Via Chartmill

Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq ↗

October 15, 2026

Via Chartmill

Topics Economy

Discover which dow jones stocks are making waves on Wednesday. ↗

October 14, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Merck & Co (NY:MRK)

All News about Merck & Co

Sections

Services